Malignant transformation of giant cell tumour of the bone is extremely rare. In addition, bone transformation in giant cell tumour may occur in different phases. With conventional X-rays, CT scans or MRIs, it may be challenging to distinguish among different phases of bone transformation, normal bone, soft tissue disease and bone disease (benign vs malignant lesions) and changes in multiple organs such as lung, liver and lymph nodes unless every lesion is biopsied, which is not practical. Molecular imaging with different isotopes (Tc-99m phosphonate, 2-deoxy-2-(18F)fluoro-d-glucose and sodium fluoride-18) may help to better characterise the disease. We hypothesised that molecular imaging could offer qualitative and quantitative characterisation of all stages of bone formation, destruction, reactivity or neoplasia in a patient with giant cell tumour of the bone, and we present the first case of molecular imaging where bone formation was seen in multiple soft tissues, such as lungs, muscles, lymph nodes and liver.
- cancer intervention
- screening (oncology)
Statistics from Altmetric.com
Contributors KK: discuss planning, reporting, conception and design, acquisition of data or analysis and interpretation of data. W-LW: discuss planning, acquisition of data or analysis and interpretation of data. VS: discuss planning, conduct, reporting, conception and design, acquisition of data or analysis and interpretation of data.
Funding This study was funded by Shanon Wilkes Research Foundation. The University of Texas MD Anderson Cancer Center is funded by NIH/NCI Cancer CenterSupport Grant P30 CA016672 .
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Patient consent for publication Obtained
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.